Single doses of up to 732 mg have been administered intravenously to subjects in clinical trials without evidence of dose-related toxicities. There is no specific treatment for an overdose with reslizumab. If the event of an overdose, the patient should be treated supportively with appropriate monitoring as necessary FDA Label.
Based on the findings of a 6-month bioassay, reslizumab showed no evidence of carcinogenicity. In a fertility study, administration of reslizumab to parental mice at doses up to 50 mg/kg
(approximately 6 times the MRHD on an AUC basis) had no effects on male or female mating or fertility. The malignancy risk of reslizumab in humans with effects on tumor growth is not yet established FDA Label.
Reslizumab is a humanized interleukin-5 (IL-5) antagonist monoclonal antibody (IgG4 kappa) that is produced by recombinant DNA technology in murine myeloma non-secreting 0 (NS0) cells. IL-5 is a pro-inflammatory cytokine that is responsible for the growth and differentiation, recruitment, activation, and survival of eosinophils FDA Label. Elevated levels of eosinophils increase the risk for asthma exacerbations, including both allergic forms and nonallergic forms of asthma where eosinophilia is prominent. By targeting the IL-5 and disrupting its signalling pathways, reslizumab aims to inhibit eosinophil maturation and promote programmed cell death A31578.
Asthma is a chronic respiratory disease that causes inflammation in the lungs with asthma attacks that lead to severe breathing difficulties. Patients often experience persistent or exacerbating symptoms overtime despite conventional first-line therapies available. Inflammation-predominant asthma, which is chatacterized by eosinophilic infiltration of airway mucosa and elevated levels of eosinophils in the blood, sputum and BAL fluid, is associated with an increased risk for recurrent exacerbation and asthma-related hospitalizations A31579. In four double-blind, randomized, placebo?controlled trials in patients with severe asthma on currently available therapies, patients receiving reslizumab had fewer asthma attacks, and a longer time to the first attack compared to patients receiving placebo FDA Label, A31579. In addition, a significant improvement in lung function was seen, as measured by the volume of air exhaled by patients in one second L1133. Studies demonstrated that reslizumab was not effective in various asthma outcomes in patients without eosinophilia A31577.
Reslizumab was developed by Teva Pharmaceuticals. Approved by the FDA in March 2016, reslizumab is marketed under the brand name Cinqair for intravenous injection. It is injected once every four weeks via intravenous infusion. Cinqair is indicated as an add-on maintenance therapy for adults with severe asthma with an eosinophilic phenotype. It is approved for patients who have a history of severe asthma attacks (exacerbations) despite receiving their current asthma medicines. Reslizumab is marketed as Cinqaero in Europe.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Reslizumab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Reslizumab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Reslizumab. |
| Estrone | Estrone may increase the thrombogenic activities of Reslizumab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Reslizumab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Reslizumab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Reslizumab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Reslizumab. |
| Estriol | Estriol may increase the thrombogenic activities of Reslizumab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Reslizumab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Reslizumab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Reslizumab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Reslizumab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Reslizumab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Reslizumab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Reslizumab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Reslizumab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Reslizumab. |
| Equol | Equol may increase the thrombogenic activities of Reslizumab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Reslizumab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Reslizumab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Reslizumab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Reslizumab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Reslizumab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Reslizumab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Reslizumab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Reslizumab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Reslizumab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Reslizumab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Reslizumab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Reslizumab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Reslizumab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Reslizumab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Reslizumab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Reslizumab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Reslizumab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Reslizumab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Reslizumab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Reslizumab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Reslizumab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Reslizumab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Reslizumab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Reslizumab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Reslizumab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Reslizumab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Reslizumab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Reslizumab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Reslizumab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Reslizumab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Reslizumab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Reslizumab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Reslizumab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Reslizumab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Reslizumab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Reslizumab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Reslizumab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Reslizumab. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Reslizumab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Reslizumab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Reslizumab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Reslizumab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Reslizumab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Reslizumab. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Reslizumab. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Reslizumab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Reslizumab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Reslizumab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Reslizumab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Reslizumab. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Reslizumab. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Reslizumab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Reslizumab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Reslizumab. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Reslizumab. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Reslizumab. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Reslizumab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Reslizumab. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Reslizumab. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Reslizumab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Reslizumab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Reslizumab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Reslizumab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Reslizumab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Reslizumab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Reslizumab. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Reslizumab. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Reslizumab. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Reslizumab. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Reslizumab. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Reslizumab. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Reslizumab. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Reslizumab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Reslizumab. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Reslizumab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Reslizumab. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with Reslizumab. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Reslizumab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Reslizumab. |
| Eldelumab | The risk or severity of adverse effects can be increased when Eldelumab is combined with Reslizumab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Lumiliximab is combined with Reslizumab. |